Predictive clinical model of tumor response after chemoradiation in rectal cancer

Detalhes bibliográficos
Autor(a) principal: Santos, M.
Data de Publicação: 2017
Outros Autores: Silva, C., Rocha, A., Nogueira, C., Castro-Poças, F., Araujo, A., Matos, E., Pereira, C., Medeiros, R., Lopes, C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.16/2233
Resumo: Survival improvement in rectal cancer treated with neoadjuvant chemoradiotherapy (nCRT) is achieved only if pathological response occurs. Mandard tumor regression grade (TRG) proved to be a valid system to measure nCRT response. The ability to predict tumor response before treatment may significantly have impact the selection of patients for nCRT in rectal cancer. The aim is to identify potential predictive pretreatment factors for Mandard response and build a clinical predictive model design. 167 patients with locally advanced rectal cancer were treated with nCRT and curative surgery. Blood cell counts in peripheral blood were analyzed. Pretreatment biopsies expression of cyclin D1, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and protein 21 were assessed. A total of 61 single nucleotide polymorphisms were characterized using the Sequenom platform through multiplex amplification followed by mass-spectometric product separation. Surgical specimens were classified according to Mandard TRG. The patients were divided as: "good responders" (Mandard TRG1-2) and "poor responders" (Mandard TGR3-5). We examined predictive factors for Mandard response and performed statistical analysis. In univariate analysis, distance from anal verge, neutrophil lymphocyte ratio (NLR), cyclin D1, VEGF, EGFR, protein 21 and rs1810871 interleukin 10 (IL10) gene polymorphism are the pretreatment variables with predictive value for Mandard response. In multivariable analysis, NLR, cyclin D1, protein 21 and rs1800871 in IL10 gene maintain predictive value, allowing a clinical model design.
id RCAP_ffcb87e041177bbcfb6e523c911f7a1a
oai_identifier_str oai:repositorio.chporto.pt:10400.16/2233
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Predictive clinical model of tumor response after chemoradiation in rectal cancermolecular markerneoadjuvant chemoradiationneutrophil lymphocyte ratiopredictionrectal cancerSurvival improvement in rectal cancer treated with neoadjuvant chemoradiotherapy (nCRT) is achieved only if pathological response occurs. Mandard tumor regression grade (TRG) proved to be a valid system to measure nCRT response. The ability to predict tumor response before treatment may significantly have impact the selection of patients for nCRT in rectal cancer. The aim is to identify potential predictive pretreatment factors for Mandard response and build a clinical predictive model design. 167 patients with locally advanced rectal cancer were treated with nCRT and curative surgery. Blood cell counts in peripheral blood were analyzed. Pretreatment biopsies expression of cyclin D1, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and protein 21 were assessed. A total of 61 single nucleotide polymorphisms were characterized using the Sequenom platform through multiplex amplification followed by mass-spectometric product separation. Surgical specimens were classified according to Mandard TRG. The patients were divided as: "good responders" (Mandard TRG1-2) and "poor responders" (Mandard TGR3-5). We examined predictive factors for Mandard response and performed statistical analysis. In univariate analysis, distance from anal verge, neutrophil lymphocyte ratio (NLR), cyclin D1, VEGF, EGFR, protein 21 and rs1810871 interleukin 10 (IL10) gene polymorphism are the pretreatment variables with predictive value for Mandard response. In multivariable analysis, NLR, cyclin D1, protein 21 and rs1800871 in IL10 gene maintain predictive value, allowing a clinical model design.This study was supported by a research grant from the Associação de Apoio ao Departamento de Cirurgia do HSA and from DEFI/CHP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Impact JournalsRepositório Científico do Centro Hospitalar Universitário de Santo AntónioSantos, M.Silva, C.Rocha, A.Nogueira, C.Castro-Poças, F.Araujo, A.Matos, E.Pereira, C.Medeiros, R.Lopes, C.2018-08-28T11:26:13Z2017-07-282017-07-28T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.16/2233engOncotarget. 2017 Jul 28;8(35):58133-581511949-255310.18632/oncotarget.19651info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-10-20T10:59:41Zoai:repositorio.chporto.pt:10400.16/2233Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:38:27.451125Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Predictive clinical model of tumor response after chemoradiation in rectal cancer
title Predictive clinical model of tumor response after chemoradiation in rectal cancer
spellingShingle Predictive clinical model of tumor response after chemoradiation in rectal cancer
Santos, M.
molecular marker
neoadjuvant chemoradiation
neutrophil lymphocyte ratio
prediction
rectal cancer
title_short Predictive clinical model of tumor response after chemoradiation in rectal cancer
title_full Predictive clinical model of tumor response after chemoradiation in rectal cancer
title_fullStr Predictive clinical model of tumor response after chemoradiation in rectal cancer
title_full_unstemmed Predictive clinical model of tumor response after chemoradiation in rectal cancer
title_sort Predictive clinical model of tumor response after chemoradiation in rectal cancer
author Santos, M.
author_facet Santos, M.
Silva, C.
Rocha, A.
Nogueira, C.
Castro-Poças, F.
Araujo, A.
Matos, E.
Pereira, C.
Medeiros, R.
Lopes, C.
author_role author
author2 Silva, C.
Rocha, A.
Nogueira, C.
Castro-Poças, F.
Araujo, A.
Matos, E.
Pereira, C.
Medeiros, R.
Lopes, C.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Centro Hospitalar Universitário de Santo António
dc.contributor.author.fl_str_mv Santos, M.
Silva, C.
Rocha, A.
Nogueira, C.
Castro-Poças, F.
Araujo, A.
Matos, E.
Pereira, C.
Medeiros, R.
Lopes, C.
dc.subject.por.fl_str_mv molecular marker
neoadjuvant chemoradiation
neutrophil lymphocyte ratio
prediction
rectal cancer
topic molecular marker
neoadjuvant chemoradiation
neutrophil lymphocyte ratio
prediction
rectal cancer
description Survival improvement in rectal cancer treated with neoadjuvant chemoradiotherapy (nCRT) is achieved only if pathological response occurs. Mandard tumor regression grade (TRG) proved to be a valid system to measure nCRT response. The ability to predict tumor response before treatment may significantly have impact the selection of patients for nCRT in rectal cancer. The aim is to identify potential predictive pretreatment factors for Mandard response and build a clinical predictive model design. 167 patients with locally advanced rectal cancer were treated with nCRT and curative surgery. Blood cell counts in peripheral blood were analyzed. Pretreatment biopsies expression of cyclin D1, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and protein 21 were assessed. A total of 61 single nucleotide polymorphisms were characterized using the Sequenom platform through multiplex amplification followed by mass-spectometric product separation. Surgical specimens were classified according to Mandard TRG. The patients were divided as: "good responders" (Mandard TRG1-2) and "poor responders" (Mandard TGR3-5). We examined predictive factors for Mandard response and performed statistical analysis. In univariate analysis, distance from anal verge, neutrophil lymphocyte ratio (NLR), cyclin D1, VEGF, EGFR, protein 21 and rs1810871 interleukin 10 (IL10) gene polymorphism are the pretreatment variables with predictive value for Mandard response. In multivariable analysis, NLR, cyclin D1, protein 21 and rs1800871 in IL10 gene maintain predictive value, allowing a clinical model design.
publishDate 2017
dc.date.none.fl_str_mv 2017-07-28
2017-07-28T00:00:00Z
2018-08-28T11:26:13Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.16/2233
url http://hdl.handle.net/10400.16/2233
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Oncotarget. 2017 Jul 28;8(35):58133-58151
1949-2553
10.18632/oncotarget.19651
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Impact Journals
publisher.none.fl_str_mv Impact Journals
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133645714227200